Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the U.S. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?
Get the answers in Market Access Impact: Rheumatoid Arthritis (US).
Based on a survey of 100 rheumatologists, the report covers 11 major therapies from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Regeneron, Sanofi, Pfizer, Roche, and UCB. Handy graphs and charts show you how seven barriers affect your market share, revealing which competitors you gain share from, and lose it to.